cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Mohammad Rizki Fadhil Pratama
Contact Email
mohammadrizkifadhilpratama@umpr.ac.id
Phone
+6287815093560
Journal Mail Official
bjop@umpr.ac.id
Editorial Address
Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya Building B 1st Floor, RTA Milono St. Km.1,5. Palangka Raya 73111, INDONESIA
Location
Kota palangkaraya,
Kalimantan tengah
INDONESIA
Borneo Journal of Pharmacy
Published by Universitas Muhammadiyah Palangkaraya
ISSN : -     EISSN : 26214814     DOI : https://doi.org/10.33084/bjop
Core Subject : Health,
Medicine & Pharmacology
Borneo Journal of Pharmacy publishes various scientific articles covering Pharmacy and Pharmaceutical Sciences in the field but not limited to: Pharmacology-Toxicology, including pharmacokinetics, pharmacodynamics, pharmacotherapy, and toxicology. Pharmacognosy-Phytochemistry, including pharmacognosy, phytochemistry, ethnobotany, and ethnopharmacology. Pharmaceuticals, including biopharmaceuticals, pharmaceutical technology, formulations, and biotechnology. Analytical Pharmacy-Medicinal Chemistry, including pharmaceutical chemistry, chemical analysis, medicinal chemistry, bioinformatics, pharmacy physics, pharmaceutical analysis, and method validation. Microbiology Pharmacy, including the antibacterial, antifungal, and antiviral activity test. Natural Product Development, including testing the pharmacological activity of extracts, fractions, and plant isolates. Clinical-Community Pharmacy, including monitoring usage, side effects, counseling, and drug use evaluation. Management Pharmacy, including drug management, drug use profiles, pharmaceutical administration, and marketing.
Arjuna Subject : Pharmacology, Toxicology and Pharmaceutics - Pharmacology, Toxicology and Pharmaceutics (Lain-Lain)
Articles 326 Documents
 29   30   31   32   33 
Evaluation of Clove Volatile Extract Vaporizer Mats for Mosquito Control Against Aedes aegypti: Bioassay and Computational Analysis Mochammad Aqilah Herdiansyah; Rifaid Nur Arsad; Rosalia Nuril Qolbi; Inge Permatasari; Etik Ainun Rohmah; Sri Subekti; Siti Fatimatuz Zahra; Kris Cahyo Mulyatno; Intan Ayu Pratiwi; Zubaidah Ya’cob; Win Darmanto
Borneo Journal of Pharmacy Vol. 9 No. 2 (2026): Borneo Journal of Pharmacy
Publisher : Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33084/bjop.v9i2.11189

Abstract

Syzygium aromaticum contains bioactive compounds that may serve as natural alternatives to synthetic mosquito control agents. This study aimed to evaluate the mosquitocidal activity of stem, leaf, and bud extracts of S. aromaticum, formulated as vaporizer mats, against Aedes aegypti and to identify potential molecular targets of the major compounds in these extracts through computational analysis. Volatile extracts from stems, leaves, and buds were prepared by ethanol maceration and formulated into vaporizer mats at concentrations of 0.5% and 1%. A total of 525 adult A. aegypti (F330 strain) were exposed under controlled laboratory conditions in accordance with WHO guidelines. Mortality, LT50, and LT90 values were recorded after exposure. Molecular docking was performed against odorant-binding protein AaegOBP1 and pyruvate kinase (PK1), followed by molecular dynamics simulation. Among all treatments, bud extract at 1% produced the highest mortality (33%), compared with 2% in the negative control. LT50 and LT90 values for this treatment were 1.468 minutes and 50.543 minutes, respectively, indicating prolonged biological activity. Docking analysis showed that β-caryophyllene had the strongest affinity toward AaegOBP1 (-8.4 kcal/mol), while chavicol showed the strongest interaction with PK1 (-6.5 kcal/mol). Molecular dynamics simulation confirmed stable ligand-receptor interactions with RMSF values below 3 Å. These findings indicate that S. aromaticum bud extract has moderate mosquitocidal potential in vaporizer mat formulation and may act through olfactory disruption and metabolic interference in A. aegypti.
Integration of Chitosan and Ageratum conyzoides Extract in Hydrogel Patches for Enhanced Wound Closure Kinetics under the TIME Framework Malinda Prihantini; Yance Anas; Junvidya Heroweti; Dewi Andini Kunti Mulangsri; Wahyudin Bin Jamaludin; Luthfia Mufaridhotun Nahla; Reyhan Raka Mahadika; Fazdilatul Hawa; Nayla Azkya; Rifka Sephia Fassadila
Borneo Journal of Pharmacy Vol. 9 No. 2 (2026): Borneo Journal of Pharmacy
Publisher : Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33084/bjop.v9i2.11198

Abstract

Chronic wounds pose a significant healthcare challenge in Southeast Asia, with prevalence rates reaching 50.8%. Conventional systemic therapies often fail due to persistent inflammation and bacterial biofilm formation. This study presents a novel approach that combines chitosan, a hydrophilic scaffold that maintains optimal moisture and prevents microbial contamination, with Ageratum conyzoides, which is rich in flavonoids with anti-inflammatory and pro-proliferative properties. This study aimed to evaluate the impact of chitosan combined with A. conyzoides in a hydrogel patch formulation on wound healing as a comprehensive approach to the TIME (Tissue, Inflammation, Moisture, Epithelization) concept. The standardized plant material was formulated into patches by a solvent‐casting method using three extract‐to‐chitosan ratios: F1 (2:0), F2 (1:1), and F3 (2:1). Evaluation encompassed physical characterization, acute dermal irritation, and wound‐healing activity assessment. Plant material met the Indonesian Herbal Pharmacopeia standards, yielding 9.96 ± 0.10% total flavonoid content, with phytochemical screening confirming flavonoids, phenolics, and quinones. All formulations demonstrated favorable physical characteristics: thickness of 0.08–0.11 mm, folding endurance of 64–479 folds, and moisture absorption of 6.12–9.39%, with no acute dermal irritation observed in rabbits. In a 14-day linear incision wound model using male Wistar rats, F3 achieved superior healing efficacy (97% closure, rate constant 0.2972 day⁻¹), reaching 90% closure by day 7.75, significantly outperforming the positive control (Bioplacenton®, 89%) and negative control (79%). These results highlight F3's synergistic effects via anti-inflammatory and proliferative mechanisms, following first-order kinetics and comprehensively addressing the TIME framework to enhance wound healing.
Analysis of Antibiotic Use in Outpatient Pneumonia Patients at X Blitar Health Center using the Gyssens Method and the Defined Daily Dose Hesti Rima Hariyani; Rina Widiyawati; Fauna Herawati; Nurul Chusna
Borneo Journal of Pharmacy Vol. 9 No. 2 (2026): Borneo Journal of Pharmacy
Publisher : Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33084/bjop.v9i2.11327

Abstract

Pneumonia is one of the respiratory infections that is still a public health problem and requires appropriate antibiotic therapy. However, irrational use of antibiotics has the potential to increase resistance and worsen patient clinical outcomes. This study aims to analyze antibiotic use in outpatient pneumonia patients at the X Blitar Health Center using the Defined Daily Dose (DDD) and Gyssens methods. This study employed a cross-sectional approach, utilizing secondary data from 109 medical records and prescriptions for pneumonia patients (ICD-10 codes J12-J18) from February 2024 to May 2025. Quantitative analysis was conducted using the DDD/1,000 patients per day method, while qualitative analysis of prescriptions was performed using the Gyssens method. The results showed that Amoxicillin (J01CA04) was the most widely used antibiotic, namely 232.42 DDD/1,000 patients per day, followed by Cefadroxil (87.04 DDD/1,000 patients per day), Ciprofoxacin (18.35 DDD/1,000 patients per day), and Azithromycin (15.29 DDD/1,000 patients per day). Gyssens' analysis revealed that most prescriptions fell into categories IIA (33.94%), IVA (29.36%), and V (27.52%). Inaccurate dosage and suboptimal antibiotic selection were the leading causes of irrational antibiotic use. Additionally, 30 pneumonia patients were identified who did not receive antibiotics despite having clinical indications for them. The results of this study emphasize the need for rationalization training in therapy, prescription audits, and the strengthening of clinical guidelines implementation in primary care facilities.
Rapid and Controlled: Microflow Reactor-Assisted Synthesis of Cinnamaldehyde and Ethyl Cinnamate along with Their Cytotoxic Activity Against Several Cell Lines Nindita Fransiska Rahmawati; Muhtadi Muhtadi; Andi Suhendi; Ahmad Fauzi; Didin Mujahidin; Ahwan Ahwan; Agustono Wibowo
Borneo Journal of Pharmacy Vol. 9 No. 2 (2026): Borneo Journal of Pharmacy
Publisher : Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33084/bjop.v9i2.11781

Abstract

Cinnamaldehyde is a major aromatic compound utilized in the pharmaceutical industry due to its diverse biological activities, including anticancer potential. This study aims to develop a rapid and controlled synthesis method for cinnamaldehyde and ethyl cinnamate using microflow reactor technology, followed by structural elucidation and cytotoxic evaluation against HeLa, MCF-7, and T47D cancer cell lines. The synthesis of cinnamaldehyde was performed via aldol condensation of benzaldehyde and acetaldehyde (1.3:1 molar ratio) at 70°C, while ethyl cinnamate was synthesized through a two-step process involving Pinnick oxidation and Fischer esterification. The results demonstrated that microflow synthesis achieved a cinnamaldehyde yield of 52% with high purity (100% based on HPLC relative area), and ethyl cinnamate with 99% purity. In cytotoxic assays, synthesized cinnamaldehyde exhibited moderate activity, most notably against HeLa cells with an IC₅₀ of 95 µg/mL, whereas ethyl cinnamate showed lower potency (IC₅₀ > 200 µg/mL). Although the synthesized compounds were less potent than the standard cinnamaldehyde (IC₅₀ 1.56 µg/mL) and Doxorubicin control, this study confirms that microflow reactor technology is a highly effective and time-efficient method for producing high-purity cinnamate derivatives.
Cover, Content, and Editorial Note from Borneo J Pharm Vol. 9 No. 1 March 2026: Advancing Natural Heritage, Clinical Optimization, and In Silico Innovations Chief Editor of Borneo J Pharm
Borneo Journal of Pharmacy Vol. 9 No. 1 (2026): Borneo Journal of Pharmacy
Publisher : Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33084/bjop.v9i1.13262

Abstract

Assalamu'alaikum Wr. Wb. Alhamdulillahirabbil 'alamin. The next edition of Borneo Journal of Pharmacy (Borneo J Pharm) has been published in March 2026. This edition contains twelve articles spanning: Pharmacology-Toxicology, Pharmacognosy-Phytochemistry, Pharmaceutics, Analytical Pharmacy-Medicinal Chemistry, Microbiology Pharmacy, Natural Product Development, Community Pharmacy, and Clinical Pharmacy Practice. This edition includes writings from three countries: Indonesia, Malaysia, and the Philippines. The authors come from several institutions, including Universitas Muhammadiyah Surakarta, Universitas Muhammadiyah Pekajangan Pekalongan, Universitas Lambung Mangkurat, Universitas Islam Bandung, Universitas Hasanuddin, Akademi Farmasi Yarsi Pontianak, Universitas Jember, Universiti Sains Malaysia, Universitas Jenderal Ahmad Yani, Universitas Tanjungpura, Universitas Ahmad Dahlan, National Research and Innovation Agency (BRIN), Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin, Universitas Airlangga, Universitas Surabaya, Our Lady of Fatima University, De La Salle University, Universiti Teknologi MARA, and Universitas Mulawarman. This edition underscores the multifaceted nature of the pharmaceutical sciences in Southeast Asia, featuring research that seamlessly spans the "bench-to-bedside-to-silico" spectrum. The articles in this issue highlight the immense potential of local and marine biodiversity, advancements in drug delivery systems, critical evaluations of clinical outcomes, and the evolving regulatory and predictive frameworks guiding therapeutic development. Validating Bioactive Prospects and Chemodiversity in Regional Ecosystems A significant portion of this issue is dedicated to the scientific validation of Southeast Asia's rich terrestrial and marine heritage, particularly focusing on optimal compound recovery and therapeutic applications for chronic metabolic and non-communicable diseases: pH-Modulation and Marine Extraction: Research on Rhizophora stylosa (Mangrove) leaves demonstrates that altering solvent alkalinity influences metabolite solubility, showing that a pH 10 ethanolic system maximizes phenolic yields and radical-scavenging capacity while maintaining structural chromophore integrity. Complementing marine discovery, an evaluation of carrageenan extracts from nine edible seaweed species native to the Western Visayas catalogs distinct phytochemical fingerprints and free-radical-scavenging potential profiles via DPPH assays. Preclinical Validation of Antidiabetic and Anti-inflammatory Potency: Combining empirical profiling with computer models, a study on Tithonia diversifolia (Insulin leaf) identifies key therapeutic flavonoids (hispidulin, luteolin, and genistein) and demonstrates their superior ability to inhibit α-amylase and intercept glycated hemoglobin (HbA1c) formation compared to standard glibenclamide. Additionally, the in vivo anti-inflammatory efficacy of Syzygium polyanthum (Salam) leaf extract is validated in animal models, demonstrating consistent reductions in carrageenan-induced paw edema. Breakthroughs in Computational Chemistry and Bioinformatics Moving beyond laboratory assays, this issue highlights the growing role of advanced data mining, virtual screening, and structural mathematical simulations in accelerating drug discovery: High-Throughput Docking and QSAR Modeling: Research on Pluchea indica (Beluntas) uses an in silico library to screen 110 phytoconstituents, identifying competitive natural inhibitors of Angiotensin-Converting Enzyme (ACE) to treat hypertension. Similarly, structural molecular docking combined with Quantitative Structure-Activity Relationship (QSAR) mathematical frameworks evaluates newly synthesized N-(ethylcarbamothioyl)benzamide derivatives as dual estrogen-α and progesterone receptor inhibitors for targeted breast cancer therapy. Pharmacokinetic and Genomic Simulations: A short communication maps the absorption, distribution, metabolism, excretion, and toxicity (ADMET) parameters of critical antiviral agents, such as Remdesivir and Favipiravir, and optimizes data on their active clearance and metabolite elimination profiles. Furthermore, an in silico bioinformatics pipeline analyzes deep genomic repositories (Ensembl, Haploreg, GTEx) to pinpoint specific single-nucleotide polymorphisms (SNPs) and structural variants driving neuropathic pain pathways in diabetic neuropathy. Innovations in Chemical Synthesis and Topical Formulations Connecting raw starting blocks with targeted delivery systems, researchers in this issue present key structural and formulation optimizations: Reflux Kinetics in Chemical Synthesis: A study investigating the Knoevenagel-Doebner condensation reaction optimizes reflux timelines using malonic acid and 4-hydroxybenzaldehyde, defining the precise reaction durations needed to maximize the yield and analytical purity of synthesized 4-hydroxycinnamic acid. Polymer Base Optimization and Safety Screening: In pharmaceutics, an optimization matrix evaluates the combination of HAMINT™ and HPMC K100M polymers to enhance the physical stability and topical delivery of diclofenac sodium gel creams. Parallel to base optimization, the safety profile of facial cleansing gels containing ethyl acetate and ethanol fractions of Citrus amblycarpa peel is established using the in vivo Hen's Egg Chorioallantoic Membrane (HET-CAM) vascular assay to assess potential systemic mucosal irritation. Advancing Clinical Pharmacy and Public Health Screening In the clinical and community practice sectors, this issue features structural validation matrices and proactive screening tools designed to directly improve patient outcomes: Osteoporosis Screening in Community Pharmacy: A cross-sectional pilot study in Malaysia utilizes the Malaysian Osteoporosis Screening Tool (MOST) within community pharmacies, effectively categorizing bone health risks in post-menopausal women while tracking the direct impacts of dietary intake and lifestyle choices. Medication Error Assessment in Geriatric Care: Transitioning to Institutional Patient Safety, research outlines the formal expert validation of a structured Medication Error Assessment Tool within the Integrated Medicine Management (IMM) model. Utilizing multi-disciplinary expert panels, this framework establishes a reliable tool to significantly reduce clinical medication errors in geriatric patients suffering from Congestive Heart Failure (CHF). The editorial board is fully aware that there is still room for improvement in this edition; hence, with all humility, we are willing to accept constructive suggestions and feedback to improve the publication in future editions. The editorial board would like to thank all editors, reviewers, and contributors of the scientific articles who have provided the repertoire in this issue. We hope that all parties, especially the contributors, will re-participate in the publication in the next edition, scheduled for June 2026. Wassalamu'alaikum Wr. Wb. Palangka Raya, March 2026 Editor-in-Chief
Cover, Content, and Editorial Note from Borneo J Pharm Vol. 9 No. 2 June 2026 Mohammad Rizki Fadhil Pratama
Borneo Journal of Pharmacy Vol. 9 No. 2 (2026): Borneo Journal of Pharmacy
Publisher : Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33084/bjop.v9i2.13482

Abstract

Assalamu'alaikum Wr. Wb. Alhamdulillahirabbil 'alamin. The next edition of Borneo Journal of Pharmacy (Borneo J Pharm) has been published in June 2026. This edition contains twelve articles spanning: Pharmacology-Toxicology, Pharmacognosy-Phytochemistry, Pharmaceutics, Analytical Pharmacy-Medicinal Chemistry, Microbiology Pharmacy, Natural Product Development, Community Pharmacy, and Clinical Pharmacy Practice. This edition includes writings from three countries: Indonesia, Malaysia, and South Korea.The editorial board is fully aware that there is still room for improvement in this edition; hence, with all humility, we are willing to accept constructive suggestions and feedback to improve the publication in future editions. The editorial board would like to thank all editors, reviewers, and contributors of the scientific articles who have provided the repertoire in this issue. We hope that all parties, especially the contributors, will participate again in the publication of the next edition, scheduled for September 2026. Wassalamu'alaikum Wr. Wb. Palangka Raya, June 2026 Editor-in-Chief

Page 33 of 33 | Total Record : 326

 29   30   31   32   33 

Filter by Year

2018 2026


Reset
Filter By Issues
All Issue Vol. 9 No. 2 (2026): Borneo Journal of Pharmacy Vol. 9 No. 1 (2026): Borneo Journal of Pharmacy Vol. 8 No. 4 (2025): Borneo Journal of Pharmacy Vol. 8 No. 3 (2025): Borneo Journal of Pharmacy Vol. 8 No. 2 (2025): Borneo Journal of Pharmacy Vol. 8 No. 1 (2025): Borneo Journal of Pharmacy Vol. 7 No. 4 (2024): Borneo Journal of Pharmacy Vol. 7 No. 3 (2024): Borneo Journal of Pharmacy Vol. 7 No. 2 (2024): Borneo Journal of Pharmacy Vol. 7 No. 1 (2024): Borneo Journal of Pharmacy Vol. 6 No. 4 (2023): Borneo Journal of Pharmacy Vol. 6 No. 3 (2023): Borneo Journal of Pharmacy Vol. 6 No. 2 (2023): Borneo Journal of Pharmacy Vol. 6 No. 1 (2023): Borneo Journal of Pharmacy Vol. 5 No. 4 (2022): Borneo Journal of Pharmacy Vol. 5 No. 3 (2022): Borneo Journal of Pharmacy Vol. 5 No. 2 (2022): Borneo Journal of Pharmacy Vol. 5 No. 1 (2022): Borneo Journal of Pharmacy Vol. 4 No. 4 (2021): Borneo Journal of Pharmacy Vol. 4 No. 3 (2021): Borneo Journal of Pharmacy Vol. 4 No. 2 (2021): Borneo Journal of Pharmacy Vol. 4 No. 1 (2021): Borneo Journal of Pharmacy Vol. 3 No. Special-1 (2020): Borneo Journal of Pharmacy: COVID-19 Vol. 3 No. 4 (2020): Borneo Journal of Pharmacy Vol. 3 No. 3 (2020): Borneo Journal of Pharmacy Vol. 3 No. 2 (2020): Borneo Journal of Pharmacy Vol. 3 No. 1 (2020): Borneo Journal of Pharmacy Vol. 2 No. 2 (2019): Borneo Journal of Pharmacy Vol. 2 No. 1 (2019): Borneo Journal of Pharmacy Vol. 1 No. 2 (2018): Borneo Journal of Pharmacy Vol. 1 No. 1 (2018): Borneo Journal of Pharmacy More Issue